Selinexor(Xpovio)

As a prescription drug targeting XPO1, selinexor has been approved for marketing successively in the United States, Israel, the United Kingdom and EU member states. It shall be used strictly in accordance with medical advice.

Target of Action

XPO1

Dosage and Administration

Route and frequency of administration of selinexor: oral administration.

The dosage of selinexor should be adjusted according to the patient’s actual condition. For specific circumstances, please consult a doctor and strictly follow medical advice.

Recommended reading: Dosage and Administration of Selinexor

Adverse Reactions

Common adverse reactions: fatigue, numbness, tingling or burning pain in hands and feet, etc.

Serious adverse reactions: thrombocytopenia, leukopenia, etc.

Reference article: Adverse Reactions of Selinexor

Use in Special Populations

Pregnancy: Effective contraceptive measures should be taken during treatment with selinexor and within 1 week after the last dose. If you become pregnant or suspect you may be pregnant during selinexor treatment, please inform your healthcare provider immediately.

Lactation: Do not breastfeed during treatment with selinexor and within 1 week after the last dose. It is currently unknown whether selinexor is excreted in human milk.

Daily Precautions

1. Take selinexor strictly as prescribed. The tablets should be swallowed whole with water and must not be broken, chewed, crushed or split.

2. If a dose is missed, delayed, or vomiting occurs after administration, take the next dose at the next regular scheduled time and date. Do not take an extra dose to make up for the missed or vomited dose.

3. Dexamethasone and prophylactic antiemetics must be taken concomitantly in strict accordance with the prescription.

from FDA，2022.07